Exclusion criteria included fecal impaction, mechanical bowel obstruction, constipation not attributed to postprocedure opioid use, calculated creatinine clearance less than 50 mL/min, and ...

After 14 days of treatment, 64.6% of the patients taking ... More information: Jun Hamano et al, Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind ...

Dulcolax and Colace can also be used for opioid-induced constipation ... about what OTC options are best for your specific ...

I have several comments: Every textbook stresses the importance of routine early administration of laxatives when opioid treatment is started, in order to treat any constipation—a common side ...

Stomachaches and pains can occur for various reasons, including constipation, gas, and heartburn. In some cases, ...

Here, we report the preventive effect of naldemedine versus placebo for constipation in patients with cancer starting an opioid therapy in a multicenter ... adverse events occurring during the ...

Rizmoic is a once-daily 200-microgram oral tablet for the treatment of opioid induced constipation (OIC) in adult patients previously treated with a laxative. Shionogi received EU marketing ...

Methylnaltrexone bromide 8mg/0.4mL, 12mg/0.6mL; soln for SC inj. Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its ...

albeit off-label use for methylnaltrexone—that being for the treatment of acute constipation that occurs as a consequence of postoperative opioid-mediated analgesia in patients following ...

Opiate induced constipation is undoubtedly ... Müller-Lissner S: The pathophysiology, diagnosis and treatment of constipation [Obstipation – Pathophysiologie, Diagnose und Therapie].

Rizmoic is a once-daily 200-microgram oral tablet for the treatment of opioid induced constipation (OIC) in adult patients previously treated with a laxative. Shionogi received EU marketing ...